US10,702,600 B1
Issued: July 7, 2020
Assignee: ModernaTX, Inc.
Title: Betacoronavirus mRNA vaccine
Core Tech: mRNA vaccine coding for SARS‑CoV‑2 spike protein formulated in lipid nanoparticles (LNPs).
This patent is widely recognized as covering Moderna’s core Spikevax® COVID‑19 vaccine technology.
What the Patent Covers
U.S. 10,702,600 B1 protects key inventions around:
- mRNA vaccine compositions containing RNA sequences whose open reading frames encode antigenic proteins — particularly the spike (S) protein of betacoronaviruses such as SARS‑CoV‑2.
- Formulations in which that mRNA is delivered using lipid nanoparticles that improve stability and cellular uptake. These LNP‑based vaccines enable efficient delivery of the mRNA into human cells to trigger an immune response.
- Methods of inducing immunity by administering these mRNA vaccines to subjects to prevent or treat coronavirus infections.
In practice, the inventions claimed by this patent formed the technical foundation for Moderna’s mRNA‑1273 vaccine (marketed as Spikevax®), which played a major role in the global pandemic response.
Why This Patent Is Important
1. Underlies a Blockbuster Vaccine
The mRNA‑1273 vaccine was authorized for emergency use in the U.S. in December 2020, marking Moderna’s first commercially approved mRNA product. It quickly became one of the top‑selling vaccines worldwide, helping Moderna generate billions in revenue across 2021–2023.
2. Strategic IP in the mRNA Era
Although patent rights around COVID‑19 vaccines are complex and contested — including disputes over patent scope and whether Moderna can enforce all claims — this patent was intended to secure core IP protection for Moderna’s vaccine design and delivery platform.
3. Central in Patent Disputes
This patent (and related filings) has been at the heart of international legal battles over mRNA vaccine rights. Competitors like Pfizer/BioNTech have challenged Moderna’s claims, and some have even been invalidated or disputed in patent trials, reflecting how economically valuable and strategically critical this technology is to the mRNA field.
Summary
- Patent: U.S. 10,702,600 B1 — Betacoronavirus mRNA vaccine
- Issued: July 7, 2020
- Assignee: ModernaTX, Inc.
- Focus: mRNA vaccine compositions encoding the SARS‑CoV‑2 spike protein and their LNP formulations
- Importance: Forms the intellectual foundation of Spikevax®, Moderna’s COVID‑19 vaccine that generated blockbuster revenue and worldwide impact during and after the pandemic — one of the most lucrative biotech inventions associated with Moderna
BioTech IP Review 
Leave a comment